Weight Watchers' decision to move into the new business area of facilitating access to obesity drugs could represent a commercial boon to manufacturers of the drugs like Novo Nordisk A/S and Eli Lilly and Company. Weight Watchers – with a subscriber base of 3.5 million individuals and a nearly 60-year heritage in weight management – is in a unique position to provide guidance to patients about how and when to use drug interventions to manage weight.
A high-profile consumer brand like Weight Watchers also offers validation about the value of new obesity medicines, a therapeutic area that has faced more challenges than most when it